Lamotrigina [Spanish]
Brand names,
Lamotrigina [Spanish]
Analogs
Lamotrigina [Spanish]
Brand Names Mixture
Lamotrigina [Spanish]
Chemical_Formula
C9H7Cl2N5
Lamotrigina [Spanish]
RX_link
http://www.rxlist.com/cgi/generic/lamotrigine.htm
Lamotrigina [Spanish]
fda sheet
Lamotrigina [Spanish]
msds (material safety sheet)
Lamotrigina [Spanish]
Synthesis Reference
M. G. Baxter et al., Eur. pat. Appl. 21,121 (1981 to Wellcome Foundation); D. A. Sawyer et al., U.S. pat. 4,602,017 (1986)
Lamotrigina [Spanish]
Molecular Weight
256.091 g/mol
Lamotrigina [Spanish]
Melting Point
216-218 oC (uncorr)
Lamotrigina [Spanish]
H2O Solubility
No information avaliable
Lamotrigina [Spanish]
State
Solid
Lamotrigina [Spanish]
LogP
1.497
Lamotrigina [Spanish]
Dosage Forms
Tablet; Chewable
Lamotrigina [Spanish]
Indication
For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome; For the maintenance treatment of Bipolar I Disorder
Lamotrigina [Spanish]
Pharmacology
Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.
Lamotrigina [Spanish]
Absorption
98%
Lamotrigina [Spanish]
side effects and Toxicity
LD50=250 (mg/kg) (in rat, mice); LD50>640 orally (mg/kg) (in rat, mice) (Sawyer); Decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, rolling eyeballs
Lamotrigina [Spanish]
Patient Information
Lamotrigina [Spanish]
Organisms Affected
Humans and other mammals